Emerging antibody products and Nicotiana manufacturing
Open Access
- 1 March 2011
- journal article
- review article
- Published by Informa UK Limited in Human Vaccines
- Vol. 7 (3), 349-356
- https://doi.org/10.4161/hv.7.3.14266
Abstract
Antibody based products are not widely available to address multiple global health challenges due to high costs, limited manufacturing capacity and long manufacturing lead times. Nicotiana-based manufacturing of antibody products may now begin to address these challenges as a result of revolutionary advances in transient expression and altered glycosylation pathways. This review provides examples of emerging antibody-based products (mucosal and systemic) that could be competitive and commercially viable when the attributes of Nicotiana-based manufacturing (large scale, versatile, rapid, low cost) are utilized.Keywords
This publication has 61 references indexed in Scilit:
- Optimal and consistent protein glycosylation in mammalian cell cultureGlycobiology, 2009
- Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of PathogenesisScience, 2003
- Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in GermanyEuropean Journal of Pediatrics, 2003
- Colony-Stimulating Factor-1-Dependent Macrophages Are Responsible for IVIG Protection in Antibody-Induced Autoimmune DiseaseImmunity, 2003
- Cost‐effectiveness of palivizumab in New ZealandJournal of Paediatrics and Child Health, 2002
- Secretory ComponentImmunity, 2002
- Diffusion of Macromolecules and Virus-Like Particles in Human Cervical MucusBiophysical Journal, 2001
- Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc ReceptorScience, 2001
- Epitopes Involved in Antibody-Mediated Protection from Ebola VirusScience, 2000
- Production of antibodies in transgenic plantsNature, 1989